# 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT00119236** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** tanespimycin
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00119236
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-10
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00119236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00119236, "17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00119236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*